BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ICVS - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ICVS
X-ORIGINAL-URL:https://icvs.uminho.pt
X-WR-CALDESC:Events for ICVS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20230627T130000
DTEND;TZID=UTC:20230627T140000
DTSTAMP:20260610T092842
CREATED:20230626T092852Z
LAST-MODIFIED:20230703T093649Z
UID:10569-1687870800-1687874400@icvs.uminho.pt
SUMMARY:ICVS Seminar "Artemisinin Combination Therapy (ACT) in Africa - the beginning of the end?”
DESCRIPTION:Don´t miss José Pedro Gil “Artemisinin Combination Therapy (ACT) in Africa – the beginning of the end?”. \nPedro Gil is a molecular biologist by degree and leads a group at Dept. of Microbiology\, Tumor and Cell Biology at Karolinska Institute.\nHis main research area focuses on malaria disease and represents a composed perspective of in vivo (clinical trials)\, ex vivo and in vitro approaches.\nIn particular\, he has long standing on the identification of Plasmodium falciparum malaria genetic variation associated with in vivo (clinical) and in vitro response to combination therapy.\nTo this adds the search for a better understanding of the pharmacogenomics of native African populations\, under the pharmacological vision of a host-pathogen interaction context leading to parasite drug resistance.\nTo this end\, he has been successful in successive EDCTP-funded platforms\, namely\, WANECAM I resulting in the EMA approval of Artesunate-Pyroniridine (Pyramax®)\,\nWANECAM II\, presently running for the development of the novel KAF156-Lumefantrine combination\, and more recently the C-MARC project\, a molecular surveillance platform for artemisinin resistance in East Africa.\nHe has supervised over 17 PhD students\, having published 111 articles in indexed journal.\nPedro has also served as editor of several indexed journals\, consultant of Calouste Gulbenkian Foundation\, Partnerships for Development Program\nand grant evaluator for Wellcome Trust\, Swiss Science Foundation\, Austrian National Bank Foundation\, National Institutes of Health\, among other.
URL:https://icvs.uminho.pt/event/icvs-seminar-artemisinin-combination-therapy-act-in-africa-the-beginning-of-the-end/
ATTACH;FMTTYPE=image/png:https://icvs.uminho.pt/wp-content/uploads/2023/07/icvs_seminar_27_06_2023_event_site.png
END:VEVENT
END:VCALENDAR